Nosopharm welcomes Jacques Biton and Frédéric Hammel to its supervisory board

Lyon, France, November 5, 2019 – Nosopharm, a company dedicated to the research and development of new anti-infective drugs, today announces changes to its supervisory board: Jacques Biton has been appointed as chairman, taking over from Gilles Alberici, while Frédéric Hammel joins the board as a member, representing Elaia Partners. These appointments were effective from the start of October.

Both appointments come in a year when Nosopharm has signed a major agreement with Evotec and set as short- and medium-term goals a further round of financing and new strategic partnerships. In the longer term, the company plans to expand its pipeline and to license its drug candidates and drug discovery platform.

“I am delighted to welcome Jacques Biton and Frédéric Hammel to the supervisory board of Nosopharm. I would also like to thank Gilles Alberici, who has helped us achieve a major milestone in our development this year with the Evotec partnership, and Franck Lescure, for his support in growing the Nosopharm business,” said Philippe Villain-Guillot, chairman of the Nosopharm management board. “Jacques and Frédéric will help us to maintain this momentum and strike new agreements with biotechnology and pharmaceutical companies. Their experience and expertise will be crucial in achieving our future goals.”

Dr. Jacques Biton is a consultant with Novagreen Conseil, a specialist firm providing scientific and operational support for biotechnology, chemistry and cleantech start-ups. He brings with him 35 years of expertise in the pharmaceutical industry, particularly in antibiotics, and in the management and financing of biotechnology companies. He has more than 25 international patents to his name, covering applications in industrial biotechnology and chemistry. He holds an engineering degree in industrial biotechnology and an engineering doctorate in microbiology, enzymology and bioconversion from the University of Technology, Compiègne, France.

“Finding new classes of antibiotics is a major public health concern. Nosopharm has what it takes to become a leader in this field. It will be a great pleasure for me to support Philippe Villain-Guillot and his team in ramping up their development and leveraging their unique technology platform,” said Jacques Biton.

Frédéric Hammel is venture partner at Elaia Partners and will represent the firm on the supervisory board. He is the CEO of Ethera, a spin-off from CEA (the French Alternative Energies and Atomic Energy Commission) / CNRS (the French National Center for Scientific Research). Ethera is a start-up developing high-performance air quality solutions that combine nanoporous materials and connected devices. Frédéric has over 25 years’ experience gained in industrial companies and subsequently in technology start-ups. Prior to joining Ethera, Frédéric led projects in the life sciences sector, spanning therapeutic development, medical devices and diagnostics. Frédéric Hammel is a former student of the Ecole Normale Supérieure in Paris, France, where he obtained a master’s in biology and a postgraduate diploma in pharmacology. He also has an MBA from the Collège des Ingénieurs. In joining Nosopharm, he brings with him his expertise in the pharmaceutical industry and biotechnology business management. He has particular experience in fundraising from venture capital companies.

“I am very pleased to be joining the Nosopharm supervisory board. The company has a strong team and technology. Its innovative platform offers huge potential,” said Frédéric Hammel.

About Nosopharm

Nosopharm is a biotechnology company specialized in the research and development of new antimicrobial molecules. Nosopharm discovered and developed NOSO-502, a first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. It has developed a unique expertise in the discovery of natural bioactive products stemming from the Xenorhadbus and Photorhabdus microbial genera and in the medicinal chemistry of Odilorhabdins, the new class of antibiotics to which NOSO-502 belongs.

Founded in 2009, Nosopharm is based in Lyon, France, and has a staff of seven. To date, the company has raised a total of €4.3M ($5.2M) in private equity and received €3.8M ($4.6M) in grants from Bpifrance, IMI, DGA, Region Languedoc-Roussillon and FEDER.

www.nosopharm.com